Pinnacle Associates Ltd. lowered its position in Endocyte, Inc. (NASDAQ:ECYT) by 5.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 821,543 shares of the biopharmaceutical company’s stock after selling 50,754 shares during the period. Pinnacle Associates Ltd. owned approximately 1.94% of Endocyte worth $2,095,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the company. Schwab Charles Investment Management Inc. increased its position in Endocyte by 1.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 112,233 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 1,680 shares during the last quarter. Concannon Wealth Management LLC increased its position in Endocyte by 6.5% in the second quarter. Concannon Wealth Management LLC now owns 32,639 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 2,000 shares during the last quarter. Bank of New York Mellon Corp increased its position in Endocyte by 2.4% in the second quarter. Bank of New York Mellon Corp now owns 152,012 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 3,561 shares during the last quarter. State Street Corp increased its position in Endocyte by 2.7% in the fourth quarter. State Street Corp now owns 620,248 shares of the biopharmaceutical company’s stock valued at $1,582,000 after buying an additional 16,289 shares during the last quarter. Finally, FMR LLC increased its position in Endocyte by 0.7% in the fourth quarter. FMR LLC now owns 3,484,410 shares of the biopharmaceutical company’s stock valued at $8,885,000 after buying an additional 23,670 shares during the last quarter. 37.04% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Endocyte (NASDAQ:ECYT)

Endocyte, Inc. (NASDAQ:ECYT) traded down 4.02% during trading on Friday, hitting $2.15. The company had a trading volume of 49,314 shares. Endocyte, Inc. has a 52-week low of $1.98 and a 52-week high of $4.33. The firm’s 50 day moving average is $2.34 and its 200-day moving average is $2.81. The stock’s market capitalization is $90.88 million.

This piece of content was first reported by Financial Market News and is owned by of Financial Market News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece of content can be accessed at http://www.financial-market-news.com/endocyte-inc-ecyt-stake-lowered-by-pinnacle-associates-ltd/1321515/.

Several equities analysts recently issued reports on the company. Zacks Investment Research downgraded Endocyte from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 17th. Credit Suisse Group reissued a “buy” rating and issued a $7.00 target price on shares of Endocyte in a research report on Friday, November 11th.

In other Endocyte news, VP Christopher P. Leamon sold 23,244 shares of the firm’s stock in a transaction that occurred on Friday, December 30th. The shares were sold at an average price of $2.55, for a total value of $59,272.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 16.62% of the company’s stock.

About Endocyte

5 Day Chart for NASDAQ:ECYT

Want to see what other hedge funds are holding ECYT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endocyte, Inc. (NASDAQ:ECYT).

Receive News & Ratings for Endocyte Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte Inc. and related companies with MarketBeat.com's FREE daily email newsletter.